In conclusion, the APOE ε4 status is associated with lower CSF Aβ42 as well as higher CSF T-tau and p-tau protein levels and tau/Aβ ratios, in patients in the early prodromal stages of AD and in control subjects. The gene discussed is MAPT; the disease is Alzheimer disease.